Clinical Trials in Arizona

Showing 5241-5260 of 16,770 trials

SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

NCT01261312

Phase 1-2 dose-escalation randomized study in participants with intermediate or high risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). The Dose Escalation Segment will evaluate the biological activity, preliminary safety and efficacy of SGI-110 with two dosing schedules in MDS and AML participants while the Dose Expansion Segment will further evaluate safety and efficacy at the biological effective dose (BED) or maximum tolerated dose (MTD) as defined in the Dose Escalation Segment.

MDSCMMLAML

Astex Pharmaceuticals, Inc.414 participantsStarted Jan 2011

Scottsdale, Arizona, United States • Los Angeles, California, United States • New Haven, Connecticut, United States +13 more locations

COMPLETEDPhase 231 miles

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

NCT04247542

Segments 2A and 2B of this trial evaluate the safety, efficacy, pharmacokinetics, fecal concentrations, and fecal microbiome effects of ACX-362E \[ibezapolstat\] in patients with C. difficile infection (CDI).

Clostridium Difficile Infection

Acurx Pharmaceuticals Inc.53 participantsStarted Mar 2020

Scottsdale, Arizona, United States • Apple Valley, California, United States • Camarillo, California, United States +26 more locations

SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

Find Trials by Condition in Arizona

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

Novel Experimental COVID-19 Therapies Affecting Host Response

The OPBC-07/microNAC Study

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

ACP-104 in Acutely Psychotic Subjects With Schizophrenia

to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)

Intermediate-Size Expanded Access Protocol (EAP) for LP352

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

Non-Complex Biliary Stones DSC vs ERC

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)